Clinical Evaluation of 18F-AV-1451

Trial Profile

Clinical Evaluation of 18F-AV-1451

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Flortaucipir-F-18 (Primary)
  • Indications Alzheimer's disease; Depression; Encephalopathy
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Avid Radiopharmaceuticals
  • Most Recent Events

    • 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
    • 08 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
    • 03 Dec 2014 Status changed from not yet recruiting to recruiting as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top